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Integrative Physiology
Heart failure (HF), a leading cause of death in the Western world, often occurs as an end phase of pathological 
myocardial hypertrophy.1 Hypertrophy is initially an adaptive 
response to stresses ranging from hypertension, valve disease, 
or cardiac injury.2,3 In an attempt to normalize wall stress, car-
diomyocytes enlarge, sarcomeres reorganize, fibroblasts pro-
liferate, and hypertrophic genes, including the  so- called fetal 
gene program, are upregulated. If prolonged, these responses 
lead to chamber dilation, myocardial apoptosis, and HF.2,3
In pathological cardiac growth, the molecular pathways affect-
ing transcription lie downstream of the nodal hypertrophic signal 
transducer, Gq.1 Among these complex pathways are the class II 
histone deacetylases (HDACs). Physiologically opposed to car-
diac growth, the HDACs repress expression of key hypertrophic 
genes, primarily through inhibition of myocyte enhancer factor 
2 (MEF2).3 Genetic deletion of the class II HDAC, HDAC5, 
sensitizes mice to cardiac stress, whereas murine deletion of 
MEF2 confers cardioprotection, decreasing pathological hyper-
trophy and attenuating upregulation of the fetal gene program.4 
HDAC kinases control nuclear HDAC activity as phosphorylation 
of HDAC5 induces its nuclear export and MEF2 derepression.3–5
In This Issue, see p 947
Editorial, see p 957
We recently identified G protein-coupled receptor (GPCR) 
kinase-5 (GRK5) as a nuclear HDAC kinase, joining protein ki-
nase D (PKD) and  calmodulin- dependent kinase II (CaMKII) as 
 HDAC- mediated facilitators of cardiac growth after hypertro-
phic stimuli.5–7 This represents a novel,  non- GPCR cardiac role 
for this GRK. We showed that mice with cardiac overexpres-
sion of GRK5 demonstrate  Gq- dependent nuclear transloca-
tion of GRK5, where it can phosphorylate HDAC5 and induce 
Original received May 8, 2012; revision received July 30, 2012; accepted August 1, 2012. In July 2012, the average time from submission to first decision 
for all original research papers submitted to Circulation Research was 11.2 days.
From the Center for Translational Medicine, Thomas Jefferson University, Philadelphia, PA (J.I.G., W.J.K.); Center for Translational Medicine (E.G., 
X.S., W.J.K.) and the Department of Pharmacology (W.J.K.), Temple University School of Medicine, Philadelphia, PA; and the Department of Medicine, 
Duke University Medical Center, Durham, NC (R.T.P.).
This manuscript was sent to Elizabeth Murphy, Consulting Editor, for review by expert referees, editorial decision, and final disposition.
The  online- only Data Supplement is available with this article at http://circres.ahajournals.org/lookup/suppl/doi:10.1161/CIRCRESAHA.112. 
273367/-/DC1.
Correspondence to Walter J. Koch, MD, Center for Translational Medicine, Temple University School of Medicine, 3500 N Broad St, MERB 941, 
Philadelphia, PA 19140.  E- mail Walter.Koch@temple.edu
© 2012 American Heart Association, Inc.
Circulation Research is available at http://circres.ahajournals.org DOI: 10.1161/CIRCRESAHA.112.273367
Determining the Absolute Requirement of G Protein–Coupled 
Receptor Kinase 5 for Pathological Cardiac Hypertrophy
Short Communication
Jessica I. Gold, Erhe Gao, Xiying Shang, Richard T. Premont, Walter J. Koch
Rationale: Heart failure (HF) is often the end phase of maladaptive cardiac hypertrophy. A contributing factor is 
activation of a hypertrophic gene expression program controlled by decreased class II histone deacetylase (HDAC) 
transcriptional repression via HDAC phosphorylation.  Cardiac- specific overexpression of G proteinen–coupled 
receptor kinase-5 (GRK5) has previously been shown to possess nuclear activity as a HDAC5 kinase, promoting 
an intolerance to in vivo ventricular pressure overload; however, its endogenous requirement in adaptive and 
maladaptive hypertrophy remains unknown.
Objective: We used mouse models with global or  cardiomyocyte- specific GRK5 gene deletion to determine the absolute 
requirement of endogenous GRK5 for cardiac hypertrophy and HF development after chronic hypertrophic stimuli.
Methods and Results: Mice with global deletion of GRK5 were subjected to transverse aortic constriction. At 12 
weeks, these mice showed attenuated hypertrophy, remodeling, and hypertrophic gene transcription along with 
preserved cardiac function. Global GRK5 deletion also diminished hypertrophy and related gene expression due to 
chronic phenylephrine infusion. We then generated mice with conditional,  cardiac- specific deletion of GRK5 that also 
demonstrated similar protection from pathological cardiac hypertrophy and HF after transverse aortic constriction.
Conclusions: These results define myocyte GRK5 as a critical regulator of pathological cardiac growth after 
ventricular pressure overload, supporting its role as an endogenous (patho)-physiological HDAC kinase. Further, 
these results define GRK5 as a potential therapeutic target to limit HF development after hypertrophic stress. 
(Circ Res. 2012;111:1048–1053.)
Key Words: G protein–coupled receptor kinases ◼ cardiac hypertrophy ◼ conditional transgenic mouse
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MEF2 activity.6 Moreover, cardiac GRK5-overexpressing mice 
displayed an intolerance to ventricular pressure overload with 
potentiated maladaptive hypertrophy and accelerated HF after 
transverse aortic constriction (TAC).6 Importantly, these trans-
genic studies did not address whether endogenous GRK5 plays 
a role in the hypertrophic response.
In the present study, we used global and  cardiomyocyte- 
 specific GRK5 knockout (KO) mice to directly address the 
importance of endogenous GRK5 in cardiac hypertrophy. We 
found that GRK5 in cardiomyocytes is absolutely required for 
hypertrophic responses after stress. Further, our data indicate 
that limiting GRK5 expression in the heart can protect against 
maladaptive cardiac growth and HF development.
Methods
Generation of GRK5cKO Mice
Detailed mouse protocols are described in the Online Data 
Supplement Methods.
Surgical Procedures and Echocardiography
TAC methodology, minipump implantation, and determination of in 
vivo cardiac function and morphology are described in the Online 
Data Supplement and Methods.
RNA Analysis
Methods for RNA analysis are described in the Online Data Supplement.
Immunoblot Analysis
Detailed methods for heart subfractionation and immunoblotting are 
described in the Online Data Supplement.
Results
Global GRK5 Deletion Diminishes In Vivo  
Cardiac Hypertrophy
We subjected male global GRK5 gene knockout mice 
(GRK5gKO)8 and littermate  wild- type (WT) control mice to 
TAC. Constitutive GRK5 deletion attenuated pressure- overload- 
induced cardiac growth seen in WT mice at 12 weeks after TAC 
(Figure 1A). Cardiac dimensions were measured serially by 
echocardiography to track development of hypertrophy and left 
ventricular (LV) dilatation over 12 weeks. WT mice showed a 
quick rise in LV posterior wall thickness (LVPWT), with a peak 
thickness of 1.99±0.05 mm at 4 weeks after TAC, which then 
decreased rapidly, indicative of adverse remodeling (Figure 1B). 
Interestingly, global GRK5 deletion significantly delays the ini-
tiation of cardiac hypertrophy after TAC, as GRK5gKO mice do 
reach a similar LVPWT (1.89±0.09 mm) as WT mice but not 
until 12 weeks after TAC (Figure 1B). At the end of 12 weeks, 
GRK5gKO mice had significantly less cardiac hypertrophy as 
determined by smaller heart weighten-to-enbody weight (HW/
BW) ratios (Figure 1C). Importantly, GRK5gKO mice show no 
signs of LV dilatation via echocardiographic measurements of 
systolic LV interior diameter (LVIDs), which were significantly 
increased in  post- TAC WT mice (Figure 1D and Online Figure 
I). Further,  post- TAC GRK5gKO mice showed preserved car-
diac function as determined by ejection fraction percent (%EF) 
compared with  post- TAC WT mice that had significant LV dys-
function (Figure 1E and Online Figure I).
We have previously shown that elevated GRK5 plays a 
critical role in myocytes as an HDAC5 kinase, derepressing 
 hypertrophy- related transcription.6 Upregulation of generalized 
hypertrophy markers, including those of the fetal gene program—
atrial natriuretic factor (ANF), β-myosin heavy chain (βMHC), 
and procollagen, type Iα2 (Col1a2)—were significantly attenu-
ated in the GRK5gKO mice compared with WT mice 12 weeks 
after TAC (Figure 1F). Loss of GRK5 expression globally also 
prevented the  post- TAC upregulation of hypertrophic genes direct-
ly regulated by MEF29: brain natriuretic peptide (BNP), actin-α1 
(Acta-1), and connective tissue growth factor (CTGF) (Figure 
1G). Thus, deletion of GRK5 is protective against hypertrophy at 
the molecular level, consistent with the in vivo phenotype.
Grk5gKO Mice Are Resistant to 
 Phenylephrine- Dependent Hypertrophy
Phenylephrine (PE), acting through α-adrenergic receptors 
(αARs), induces cardiomyocyte hypertrophy in vitro and in vivo. 
Previously, we have found that PE causes GRK5 nuclear trans-
location and increased MEF2 activity in myocytes.6 Therefore, 
we tested whether endogenous GRK5 was necessary for devel-
opment of  PE- induced cardiac hypertrophy. Male mice (WT 
and GRK5gKO) were treated with a subpressor dose of PE (35 
mg/kg per day) or  phospho- buffered saline (PBS) for 14 days via 
osmotic minipumps (Figure 2A). This period covers only an initial 
hypertrophy stage without decompensation, thereby testing the 
requirement of endogenous GRK5 in myocardial α AR- mediated 
hypertrophy. PE treatment caused cardiac growth in WT mice, 
with a significant 26.9±8% increase in HW/BW ratio at 2 weeks, 
whereas GRK5gKO mice subjected to PE had only an 11.2±7% 
increase in HW/BW, insignificant compared with  PBS- treated 
GRK5gKO mice (Figure 2B). Two weeks of PE treatment does 
not change cardiac function, which is what we found for %EF 
(Figure 2C), although PE significantly altered morphology in WT 
mice (Figure 2D and 2E). Importantly,  PE- treated GRK5gKO 
mice showed no changes in cardiac dimensions (Figure 2D, 2E).
Non-standard Abbreviations and Acronyms
AR adrenergic receptor
CaMKII calmodulin-dependent kinase II
%EF ejection fraction percent
GPCR G protein–coupled receptor
GRK G protein–coupled receptor kinase
HDAC histone deacetylase
HF heart failure
HW/BW heart weight–to–body weight ratio
KO knockout
LV left ventricular
LVIDs systolic left ventricular internal diameter
LVPWT left ventricular posterior wall thickness
MEF2 myocyte enhancer factor 2
PBS phospho-buffered saline
PE phenylephrine
PKD protein kinase D
TAC transverse aortic constriction
WT wild-type
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As with  post- TAC, GRK5 deletion significantly decreased 
 PE- mediated upregulation of hypertrophy markers. Indeed, 
whereas PE led to robustly increased expression of our panel 
of hypertrophic genes in WT mice, no such upregulation was 
seen in GRK5gKO mice (Figure 2F and 2G). Overall, these 
data demonstrate that GRK5 plays a key role in cardiac hyper-
trophy downstream of PE, identical to  post- TAC phenotype.
Global GRK5 Ablation Decreases Nuclear HDAC5 
Export After Hypertrophic Stimulus
The diminished upregulation of genetic hypertrophy markers 
seen in GRK5gKO mice after TAC suggests that GRK5 can 
regulate cardiac gene transcription. This is probably due to the 
ability of GRK5 to phosphorylate HDAC5, inducing its export 
from the nucleus.6 Hence, we examined location and phosphor-
ylation of HDAC5 after hypertrophic stress in GRK5gKO and 
WT mice. Hearts from the above experiments were subjected 
to subcellular fractionation. After TAC, WT mice showed a sig-
nificantly increased amount of phosphorylated HDAC5 in the 
 non- nuclear subcellular fraction compared with GRK5gKO TAC 
mice and WT sham mice (WT TAC: 1.94±0.13;GRK5gKO TAC: 
0.91±0.14; WT sham: 1.02±0.17) (Figure 3A and 3B). Similar re-
sults were seen in the  non- nuclear fraction from WT mice that had 
received chronic infusion of PE. These mice showed significantly 
greater  non- nuclear phosphorylated HDAC5 than  PE- infused 
GRK5gKO mice and  PBS- infused WT mice (Figure 3C), further 
reinforcing the role of endogenous GRK5 as an HDAC5 kinase.
 Cardiac- Specific Deletion of GRK5 Attenuates 
Hypertrophy After TAC
The above results show that complete GRK5 ablation attenuates 
the cardiac hypertrophic response but does not address the spe-
cific role of myocyte GRK5 in maladaptation and  post- TAC HF. 
Therefore, we developed conditional GRK5KO mice in which 
GRK5 deletion was  cardiac- specific. We bred floxedGRK5 
mice with transgenic mice expressing  Cre- recombinase un-
der control of the αMHC promoter.10 These conditional GRK5 
KO (GRK5cKO) mice had >50% loss of cardiac GRK5 deter-
mined by either protein immunoblotting or  RT- PCR (Online 
Figure II). As above, we stressed GRK5cKO mice and WT 
control mice (GRK5floxed) via TAC and studied these groups 
alongside  sham- operated mice for 12 weeks (Figure 4A). Serial 
echocardiography showed significantly attenuated hypertrophy 
Figure 1. Attenuated hypertrophy seen in GRK5gKO mice after TAC. A, Hearts from WT and GRKgKO mice subjected to a sham 
operation or TAC (top). Histological sections stained are with Masson trichrome for fibrosis (middle; bottom). WT sham, n=6; WT TAC, 
n=9; gKO sham, n=6; gKO TAC, n=11. B, Systolic LVPWT measured serially by echocardiogram after sham or TAC operations. *P<0.05. 
C, HW/BW ratios were measured 12 weeks after TAC. *P<0.01. LVIDs (D) or %EF (E) as measured by echocardiogram at 12 weeks after 
TAC. *P<0.01.  RT- PCR was used to measure mRNA expression of known markers of cardiac hypertrophy (F) and genes directly regulated 
by MEF2 (G); n=8, *P<0.05.
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in GRK5cKO mice with maximally increased cardiac mass at 
12-weeks when WT mice are clearly decompensated after their 
peak hypertrophy 4 weeks after TAC (Figure 4B). This delayed 
compensatory hypertrophy led to a trend toward lower HW/BW 
ratio in GRK5cKO mice at 12 weeks after TAC compared 
with WT mice (Figure 4C). This effect is less robust than the 
GRK5gKO mice but no doubt due to incomplete GRK5 ablation. 
However, from in vivo functional studies, it is clear that the myo-
cyte GRK5 loss protects these hearts from adverse LV remodeling 
and HF, as GRK5cKO mice displayed no increased LV dilatation 
at the study’s end, compared with significantly increased LVIDs 
in WT mice (Figure 4D and Online Figure III). This protection 
against HF was also evident in global in vivo cardiac function as 
12-week  post- TAC WT mice had a significant loss of LV %EF 
compared with sham WT mice, while there was absolutely no 
drop in %EF in 12-week  post- TAC GRK5cKO mice (Figure 4E).
Again, we examined our panel of  hypertrophy- related 
genes. At 12 weeks after TAC, hearts from GRK5cKO mice 
showed significantly diminished upregulation of these com-
mon cardiac hypertrophy markers, including those of the fetal 
gene program (Figure 4F), and specific MEF2-regulated genes 
(Figure 4G). Overall, these data demonstrate that GRK5 ex-
pression in cardiomyocytes alone is required for WT molecu-
lar, functional, and morphological responses after TAC.
Discussion
Our results indicate an absolute requirement of cardiomyocyte 
GRK5 for normal hypertrophic responses and that this kinase 
plays a critical pathological role in ventricular decompensa-
tion and transition to HF after ventricular pressure overload. 
Importantly, merely decreasing cardiomyocyte GRK5 in mice 
blunts hypertrophic myocardial growth and prevents HF after 
TAC. Importantly, these data demonstrate that endogenous myo-
cyte GRK5 plays a crucial role in adaptive and maladaptive hyper-
trophy and is required for WT response to stress. Thus, increased 
GRK5 in the failing human heart11 has pathological significance, 
since lowering GRK5 or inhibiting its activity appears to offer 
novel beneficial effects against maladaptive cardiac growth.
These results in global and  cardiac- specific GRK5KO 
mice, coupled with our previous results showing that 
 GPCR- independent nuclear activity of GRK5 can facilitate hy-
pertrophy,6 indicate that nuclear targeting of endogenous GRK5 
as a class II HDAC kinase is physiologically significant in normal 
and abnormal cardiac growth after stress. Interestingly, loss of 
nuclear GRK5 activity can delay HF onset through slower car-
diac growth, although its deletion does not completely amelio-
rate hypertrophy. This may be due to compensatory and discrete 
roles of the other known HDAC5 kinases, CAMKII, and PKD, 
Figure 2. PE induces less hypertrophy in GRK5gKO mice. A, Hearts from WT and GRK5 gKO mice subjected to 2 weeks of chronic 
infusion of PBS or subpressor PE (35 mg/kg per day) (top). Histological sections are stained with Masson trichrome for fibrosis (middle; 
bottom). WT PBS, n=8; WT PE, n=10; gKO PBS, n=9; gKO PE, n=11. B, HW/BW ratios for WT and GRK5gKO mice were measured after  
2 weeks of chronic PBS or PE infusion. *P<0.05. %EF (C), LVIDs (D), and LVPWT (E) as measured by echocardiogram at 2 weeks. *P<0.05. 
 RT- PCR was used to measure mRNA expression of known markers of cardiac hypertrophy (F) or MEF2-regulated genes (G); n=8, *P<0.05.
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acting downstream of hypertrophic signaling.5,7 Each kinase has 
been shown to cause HDAC5 nuclear export after select receptor 
activation such as endothelin-1 receptor for CAMKII and αAR 
for PKD.5,12 We now can add GRK5 to the list of physiological 
HDAC kinases downstream of TAC and αAR stimulation. These 
distinct activators of HDAC kinases appear to underlie a com-
plex network of parallel signaling converging on the same tar-
get, HDAC5. Overall, our data demonstrate that targeting only 1 
Figure 3. Global GRK5 ablation decreases phosphorylated HDAC5 in the cytoplasm. A, Twelve weeks after TAC or a sham operation, 
hearts from WT and GRK5gKO mice were fractionated into  non- nuclear and nuclear fractions. HDAC5 was immunoprecipitated from the 
 non- nuclear fraction and immunoblotted for phosphorylated and total amounts (pHDAC5 and tHDAC5, respectively). B, Denistometric 
quantification of pHDAC5 normalized to tHDAC. *P<0.01 versus all groups, n=6. C, Denistometric quantification of pHDAC5 normalized to 
tHDAC5 after immunoprecipitation and immunoblotting for pHDAC5 in WT and GRK5gKO mouse hearts after 2 weeks of chronic PBS or 
PE infusion. *P<0.01 versus all groups, n=6.
Figure 4. Attenuated hypertrophy seen in GRK5cKO mice after TAC. A, Hearts from WT and GRK5cKO mice subjected to a sham operation 
or TAC (top). Histological sections are stained with Masson trichrome for fibrosis (middle; bottom). WT sham, n=9; WT TAC, n=14; cKO sham, 
n=8; cKO TAC, n=9. B, Systolic LVPWT measured serially by echocardiogram after sham or TAC operations. *P<0.05. C, HW/BW ratios for WT 
and GRK5cKO mice were measured 12 weeks after TAC. LVIDs (D) or %EF (E) as measured by echocardiogram at 12 weeks after TAC. *P<0.01. 
 RT- PCR was used to measure mRNA expression of known markers of cardiac hypertrophy (F) and MEF2-regulated genes (G); n=8, *P<0.05.
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HDAC kinase can delay HF and may be advantageous in thera-
peutic intervention by allowing some signaling.
Because GRK5 plays a dual role in the  cardiomyocyte—
membrane- associated GPCR desensitizing kinase and nuclear 
kinase facilitating transcription—the most critical activities for 
cardiac signaling and function are uncertain. Classic GRK5 ac-
tivity toward β-adrenergic receptors (βARs) has been shown to 
induce transactivation of the cardioprotective epidermal growth 
factor receptor.13 A human polymorphism of GRK5 (Q41L) ap-
pears to increase βAR desensitization, protecting some HF pa-
tients chronically.14 Additionally, transgenic overexpression of 
Gαq caused a slight cardiac dilatation in GRK5gKO mice com-
pared with WT controls.15 Therefore, there is some question as 
to whether the increased GRK5 is protective or injurious.
In the present study, simply decreasing myocyte GRK5, 
either completely in GRK5gKO mice or significantly in 
GRK5cKO mice, attenuated cardiac hypertrophy and pre-
vented pathogenesis of HF. We show that GRK5 ablation does 
not completely prevent hypertrophy but significantly delays it. 
Therefore, despite potential beneficial activities at the plasma 
membrane, removing cardiomyocyte GRK5 has a profound 
positive effect on outcomes after pressure overload and chronic 
α-adrenergic stress. Clearly, our data now indicate that GRK5, 
and, most likely, its nuclear HDAC kinase activity, represent 
a novel target to prevent maladaptive cardiac hypertrophy and 
protect against ventricular decompensation and HF.
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What Is Known?
•	 G protein-ncoupled receptor kinase 5 (GRK5) is upregulated in numer-
ous models of heart failure (HF), as well as in the failing human heart.
•	 GRK5 enters the nucleus and acts as a histone deacetylase 5 (HDAC5) 
kinase, increasing transcription of cardiac hypertrophy genes.
•	 Increased nuclear GRK5 is pathological in the setting of chronic 
pressure overload.
What New Information Does This Article Contribute?
•	 Ablation of GRK5 significantly delays maladaptive cardiac remodeling and HF 
after chronic pressure overload or α-adrenergic receptor (αAR) stimulation.
•	 Removing nuclear GRK5 by global ablation decreases HDAC5 export.
•	 Deletion of GRK5 in cardiomyocytes alone significantly delays the on-
set of HF.
Pathological cardiac hypertrophy, a process commonly ending 
in HF, occurs through activation of nodal signal transducer, Gq. 
Downstream of Gq, class II HDACs represses hypertrophic gene 
transcription. GRK5, a recently identified HDAC kinase, has 
been shown to be upregulated in human HF, although the is un-
known. Here, we investigated the role of endogenous GRK5 in 
maladaptive cardiac remodeling. Our results show that global 
and  cardiomyocyte- specific ablation of GRK5 significantly at-
tenuates pathological cardiac hypertrophy, delaying HF onset. 
This cardioprotection may be attributed to decreased nuclear 
HDAC5 export after GRK5 deletion. Overall, this study suggests 
that endogenous nuclear GRK5 plays an injurious role in mal-
adaptive hypertrophy and may represent a novel therapeutic 
target.
Novelty and Significance
 at Thomas Jefferson Universi on August 12, 2013http://circres.ahajournals.org/Downloaded from 
	   1	  
Supporting Information Materials and Methods 
 
Generation of Conditional GRK5 knockout mice.  .  All animal procedures and 
experiments were performed in accordance with the guidelines of the Institutional Animal 
Care and Use Committee of Thomas Jefferson University.  The GRK5/flox line was 
created as described in Gainetdinov et al, 19991, except that a Cre transfected, GRK5-
targeted ES cell line was selected for deletion of the TK-NEO marker cassette but 
maintenance of the exon 7/8 region of the GRK5 gene flanked by loxP sites. These 
GRK5/flox cells were microinjected into day 3.5 blastocysts (c57BL/6J) and implanted 
into pseudopregnant mice to generate founder chimeric pups.  After germline 
transmission was verified, GRK5/flox mice were backcrossed with c57BL/6J mice for 
>12 generations.  An initial cross between GRK5flox/flox and αMHC-Cre mice led to a 
cardiac-specific GRK5 deletion.  This conditional deletion was maintained by continued 
breeding of the GRK5flox/flox with GRK5flox/flox/αMHC-Cre+/-.  Only 8 week-old males from 
the above cross were utilized in our experiments.  Genotyping was performed using 
specific PCR primers designed for the loxP site.  
 
TAC.  Transverse aortic constriction was performed as described previously2.  Briefly, 8 
week-old mice were sedated in an isoflurane sedation box (induction 3% and 
maintenance 5%) and anesthetized to a surgical plane with an i.p. dose of ketamine 
(50mg/kg) and xylazine (2.5mg/kg).  Anesthetized mice were intubated using a blunt 20-
gauge needed that was connected to a volume-cycle rodent ventilator on supplemental 
oxygen at a rate of 1 L/min and respiratory rate of 140 bpm/min.  A midline cervical 
incision was made to expose the trachea, carotid arteries and rib cage.   Aortic 
constriction was performed by tying a 7.0 nylon suture ligature against a 27-gauge 
needle that was promptly removed to yield a 0.4 mm constriction.  Pressure gradients 
were determined by in vivo echocardiography of the transverse aorta and mice with 
gradients greater than 30 mmHg were used.  
 
Echocardiography.  Echocardiography was performed as previously described3.  To 
measure global cardiac function, echocardiography was performed at 8 weeks of age 
prior to TAC and at 1, 2, 4, 8, and 12 weeks post-TAC by use of the VisualSonics VeVo 
770 imagingsystem with a 707 scan head in anesthetized animals (1.5% isoflurane, 
vol/vol).  The internal diameter of the left ventricle was measure in the short-axis view 
from M-mode recordings in end diastole and end systole.  At 1-week post-TAC, pressure 
gradients were determined by PW Doppler mode. 
 
Mini-osmotic pumps.  Chronic infusion of phenylephrine (Sigma) was achieved using 
Alzet 2 week osmotic minipumps (model 2002, DURECT Corporation).  Pumps were 
filled following the manufacturer’s specifications with sterile PBS, or PE (35µM/kg/day).  
Briefly, Mice were anesthetized with isofluorane (2.5% vol/vol) and pumps were 
implanted subcutaneously through a sub-scapular incision, which was then closed using 
4.0 silk suture (Ethicon).  The contents of the pumps were delivered at a rate of 
0.5µl/hour for 2 weeks.  Mice were followed by echocardiogram prior to pump 
implantation and then weekly until the end of the 2 week period when mice were 
euthanized. 
RNA Isolation and Semiquantitative PCR.  RNA isolation and analysis was performed 
as previously described2.  Total RNA isolation was performed using the Ultraspec RNA 
Isolation System (Biotecx), according to the manufacturer’s protocol and as previously 
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described2. After RNA isolation, cDNA was synthesized from 200ng of total RNA using 
the iScript cDNA Synthesis Kit (Bio-Rad Laboratories). Semiquantitative PCR was 
carried out on cDNA using iQ SYBR Green Supermix (Bio-Rad Laboratories) and 100 
nM of the following gene-specific oligonucleotides—18S, ANF, βMHC, BNP, Col1a2, 
CTGF, and Acta-1. Quantitation was established by comparing 18s rRNA, which was 
similar between groups, for normalization. For each run, saturation of amplification 
cycles was controlled by the use of MyiQ software (version 1.0); subsequently, a melting 
curve was generated by heating the product to 95°C, cooling to and maintaining at 55°C 
for 20 seconds, and then slowly (0.5°C/s) heating to 95°C to determine the specificity of 
PCR products, which was then confirmed by gel electrophoresis.  
Immunoblot Analysis.  Isolated cardiac tissue was first homogenized using a Dounce 
homogenizer in a buffer containing: 4mM Hepes, 320mM sucrose, 10mM KCL, 5mM 
EDTA, 2mg NaF, 8mg MgCl2, .1% Triton x-10, 1.094g DTT, and protease inhibitors.  The 
homogenate was filtered through a 70µm cell filter.  Total cell lysate was taken at this 
point.  Then the lysate was subjected the same protocol as previously described for 
NRVM2.  Following subcellular fractionation, 500 µg of non-nuclear protein was 
immunoprecipitated with protein A/G and anti-HDAC5 (sc-133106, Santa Cruz). Proteins 
were subjected to SDS-PAGE, and immunoblotted with antiphospho-HDAC5 (PA1-
14187, Thermo Scientific), and anti-HDAC5 (sc-133106, Santa Cruz).  Visualization of 
Western blot signals was performed using secondary antibodies coupled to Alexa Fluor 
680 or 800 (Molecular Probes) on a LI-COR infrared imager (Odyssey).  Pictures were 
processed by Odyssey version 1.2 infrared imaging software.  All densitometry scans 
were carried out in the linear range of detection. 
Statistics.  All the values in the text and figures are presented as mean ± SEM from 
given n sizes.  Statistical significance of multiple treatments was determined by one-way 
ANOVA followed by the Bonferroni’s post hoc test when appropriate.  Statistical 
significance between two groups was determined using the two-tailed Student’s t test. P 
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Online Supplemental Figure Legends 
 
Online Fig. I Representative Echocardiogram tracings from WT and GRK5gKO mice 12 
weeks following sham or TAC operations 
 
Online Fig. II GRK5Flox/αMHC-Cre+ mice have a greater than 50% knockdown of 
GRK5.  (A) To determine GRK5 expression in our αMHC-Cre system, hearts from 
GRK5Flox/αMHC-Cre- (WT) and GRK5Flox/αMHC-Cre+ (cKO) were homogenized and 
immunoblotted for GRK5 and GAPDH.  (B) Quantitative analysis of immunoblots for 
GRK5 expression in the hearts of (A). n=4, *p<0.01.  (C) Semi-quantitative PCR was 
used to assess GRK5 mRNA levels in the hearts of WT or cKO mice.  n=6, *p<0.05 
 
Online Fig. III Representative Echocardiogram tracings from WT and GRK5cKO mice 
12 weeks following sham or TAC operations. 
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Online Supplemental Figure I 
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Online Supplemental Figure III 
 at Thomas Jefferson Universi on August 12, 2013http://circres.ahajournals.org/Downloaded from 
	   7	  
	  
 at Thomas Jefferson Universi on August 12, 2013http://circres.ahajournals.org/Downloaded from 
